2025-08-01 01:18:39
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.
After hitting a low in 2022, the number of homes listed for sale across the U.S. has been climbing over the past three years, with states like Florida and Texas leading the rise.
The infographic breaks down the active home listings of the U.S. housing market since July 2016 to the latest data as of June 2025, highlighting key regional dynamics in the housing market.
The data for this visualization comes from the Federal Reserve Bank of St. Louis, which tracks monthly housing inventory levels nationally along with counts for the states of Florida, Texas, California, and New York.
Active listings, which measure the number of homes currently for sale, have climbed up from post-pandemic lows to above one million nationally.
A mix of easing mortgage lock-in, growing new construction, and investor offloading has helped rebuild supply, but the rebound is uneven and is threatening the growth of home prices in certain states.
| Date | U.S. | Florida | Texas | California | New York |
|---|---|---|---|---|---|
| July 2016 | 1,463,025 | 136,780 | 95,456 | 83,653 | 74,565 |
| January 2017 | 1,154,139 | 141,533 | 82,622 | 58,469 | 55,071 |
| July 2017 | 1,322,676 | 133,862 | 103,727 | 71,686 | 66,901 |
| January 2018 | 1,043,968 | 133,041 | 82,060 | 52,155 | 50,144 |
| July 2018 | 1,261,936 | 134,093 | 103,071 | 78,816 | 65,518 |
| January 2019 | 1,110,654 | 150,118 | 90,985 | 69,935 | 52,436 |
| July 2019 | 1,239,557 | 134,961 | 106,695 | 82,924 | 65,235 |
| January 2020 | 951,699 | 129,170 | 86,006 | 51,831 | 49,511 |
| July 2020 | 822,849 | 106,592 | 74,650 | 50,226 | 52,671 |
| January 2021 | 531,780 | 77,534 | 47,616 | 30,995 | 39,831 |
| July 2021 | 546,697 | 51,689 | 45,796 | 39,163 | 42,544 |
| January 2022 | 376,973 | 39,961 | 36,614 | 22,698 | 28,495 |
| July 2022 | 691,663 | 73,645 | 68,582 | 59,196 | 39,156 |
| January 2023 | 616,869 | 87,717 | 72,413 | 40,126 | 30,837 |
| July 2023 | 647,145 | 83,090 | 81,594 | 39,845 | 33,717 |
| January 2024 | 665,603 | 118,163 | 83,701 | 36,174 | 28,234 |
| July 2024 | 883,905 | 141,334 | 113,622 | 57,148 | 35,155 |
| January 2025 | 829,376 | 157,221 | 102,552 | 47,924 | 28,510 |
| June 2025 | 1,082,520 | 178,636 | 138,255 | 76,737 | 37,875 |
Florida’s surge reflects climate risks, insurance spikes, and heavy homebuilding, particularly in metro areas like Tampa and Jacksonville. The state’s recent 4% drop in home prices was the biggest decline in single-family home prices since October 2011.
Texas, long known for permissive building policies, has a similar trend: resilient construction pipelines now outpacing demand, especially as higher mortgage and tax burdens push owners to list.
The housing market of the state’s capital city, Austin, saw a 5.8% YoY drop in the number of homes sold in May 2025 along with a 2% median price drop.
California, while showing a rise in inventory, remains well below pre-pandemic levels. High land and construction costs, combined with entrenched zoning restrictions, keep supply tight.
New York is even more restrained. Co-op rules, limited resale inventory, and homeowners locked into low mortgage rates have kept listings near record lows, especially in downstate markets.
With inventory coming back mostly in the Sun Belt, buyers there are gaining leverage with more choices at lower prices.
To learn more about the U.S. housing market, check out this graphic that compares income, house prices, and mortgage rates in 2025 to those in 1985.
2025-07-31 23:22:00
The pharmaceutical industry has made enormous strides in treating—and even curing—a wide range of diseases and conditions. A key driver behind this progress? Billions in funding fueling research and development (R&D) at the cutting edge.
This visualization, created in partnership with Inigo Insurance, highlights which therapeutic areas currently have the largest number of drugs in development, using data from Citeline.
The global R&D pipeline has surged over the past two decades. In 2001, just 5,995 drugs were in the pipeline. Today, that number has soared to 23,875.
Leading the pack is Pfizer, with 271 drugs in development, followed by Roche (261), Novartis (254), AstraZeneca (241), and Sanofi (233). Pharma giant Eli Lilly ranks seventh with 224 drugs.
Of the nearly 24,000 drugs in the pipeline, about half (12,704) remain in the preclinical stage, while 1,568 are projected to launch in 2025.
The biggest focus area is oncology, which accounts for 9,476 drugs—roughly 40% of the total pipeline. Neurological drugs follow at 3,868, while metabolic drugs, boosted by the weight-loss drug boom, total 3,314.
| Therapeutic Area | Number of drugs |
|---|---|
| Oncology | 9476 |
| Neurology | 3868 |
| Metabolic | 3314 |
| Infectious Disease | 2879 |
| Musculoskeletal | 2157 |
| Immunology | 1469 |
| Dermatology | 1327 |
| Sensory | 1312 |
| Cardiology | 1207 |
| Respiratory | 1172 |
| Genitourinary | 885 |
| Hematology | 811 |
| Hormonal | 273 |
| Parasitology | 109 |
| Rare diseases | 7721 |
Surprisingly, despite being the leading cause of death in the U.S., cardiovascular drugs rank ninth, with just 1,207 drugs in development.
Meanwhile, rare diseases represent another major focus, with 7,721 drugs in progress. Companies like Novartis and Bristol Myers Squibb are leading this charge, dedicating more than half of their pipelines to rare disease treatments—132 drugs (52%) and 115 drugs (50.2%), respectively.
Pharma R&D doesn’t always align with the biggest health burdens. Instead, it follows the intersection of scientific breakthroughs, patient demand, and market opportunity—a dynamic that will continue to shape the next wave of innovation.
Explore Inigo’s Hub.
Pharma giants don’t just make medicine—they shape the future of healthcare. Who are the world’s major players?
The fraud and financial crime landscapes are evolving rapidly. What are the key threats shaping risk in 2025?
Some of the largest digital heists didn’t rely on brute-force hacking, they exploited the weakest link in security: human trust.
As cybersecurity threats escalate, which financial crimes are causing the most harm? The FBI has the data.
Suspicious activity has been rising in the U.S., but is it spread evenly throughout all 50 states? Certainly not.
As technology and AI become more widespread, fraud and other suspicious activity are rising across America. Which types are the most common?
From money laundering to fraud, financial crime acts as a drain on the economy, totaling an incredible $3.1 trillion.
Over half the global population is ruled by non-centrist types of government, including autocracies and left or right wing parties.
Ukraine will require an estimated $524B over the next decade to recover from the Russia-Ukraine war. Which sectors have been most impacted?
Amid tariff increases, consumers’ expectations for U.S. inflation in the next five years have reached their highest level since March 1991.
In his first 100 days, President Trump has issued far more executive orders than any other president in history.
2025-07-31 22:12:21
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.
The race to build the next generation of global giants is on.
While public markets get most of the spotlight, private companies are quietly building massive valuations and shaping the future of industries.
This visualization ranks the world’s 50 most valuable private companies in 2025, highlighting emerging powerhouses from different countries and sectors.
The data for this visualization comes from CB Insights. It ranks private companies globally by their most recent reported valuations.
| Rank | Company | Country | Valuation ($B) |
|---|---|---|---|
| 1 |
 SpaceX |
United States | $350 |
| 2 |
 ByteDance |
China | $300 |
| 3 |
 OpenAI |
United States | $300 |
| 4 |
 Stripe |
United States | $70 |
| 5 |
 SHEIN |
Singapore | $66 |
| 6 |
 Databricks |
United States | $62 |
| 7 |
 Anthropic |
United States | $62 |
| 8 |
 xAI |
United States | $50 |
| 9 |
 Revolut |
United Kingdom | $45 |
| 10 |
 Canva |
Australia | $32 |
| 11 |
 Fanatics |
United States | $31 |
| 12 |
 Safe Superintelligence |
United States | $30 |
| 13 |
 Chime |
United States | $25 |
| 14 |
 Epic Games |
United States | $23 |
| 15 |
 Miro |
United States | $18 |
| 16 |
 Xiaohongshu |
China | $17 |
| 17 |
 Rippling |
United States | $17 |
| 18 |
 Yuanfudao |
China | $16 |
| 19 |
 DJI Innovations |
China | $15 |
| 20 |
 Discord |
United States | $15 |
| 21 |
 Gopuff |
United States | $15 |
| 22 |
 Yuanqi Senlin |
China | $15 |
| 23 |
 Ripple |
United States | $15 |
| 24 |
 Klarna |
Sweden | $15 |
| 25 |
 Anduril |
United States | $14 |
| 26 |
 Scale |
United States | $14 |
| 27 |
 OpenSea |
United States | $13 |
| 28 |
 Celonis |
Germany | $13 |
| 29 |
 Ramp |
United States | $13 |
| 30 |
 Grammarly |
United States | $13 |
| 31 |
 Devoted Health |
United States | $13 |
| 32 |
 Deel |
United States | $13 |
| 33 |
Faire |
United States | $13 |
| 34 |
 Brex |
United States | $12 |
| 35 |
 JUUL Labs |
United States | $12 |
| 36 |
 Bitmain Technologies |
China | $12 |
| 37 |
 GoodLeap |
United States | $12 |
| 38 |
 Xingsheng Selected |
China | $12 |
| 39 |
 Airtable |
United States | $12 |
| 40 |
 ZongMu Technology |
China | $11 |
| 41 |
 Global Switch |
United Kingdom | $11 |
| 42 |
Checkout.com |
United Kingdom | $11 |
| 43 |
 Bolt |
United States | $11 |
| 44 |
 Alchemy |
United States | $10 |
| 45 |
 Colossal |
United States | $10 |
| 46 |
 Huolala |
China | $10 |
| 47 |
Thinking Machines Lab |
United States | $10 |
| 48 |
 Gusto |
United States | $10 |
| 49 |
 Chehaoduo |
China | $10 |
| 50 |
 Talkdesk |
United States | $10 |
Note: Scale AI’s recent deal with Meta was not captured in the source dataset. Scale is now valued at roughly $29 billion, which would place it 14th in this ranking.
AI startups are increasingly populating the top 10, with OpenAI in third ($300 billion), Anthropic in seventh ($62 billion), and xAI in eighth ($50 billion). All three of these companies have produced some of the world’s smartest AI models in recent years.
Further down the ranking, we can identify Safe Superintelligence ($30 billion), which was created by former employees of OpenAI and Anthropic, and Scale AI, in which Meta recently acquired a 49% stake.
This deal wasn’t captured in the source dataset, but it means that Scale is now valued at $29 billion, which would bump it up to 14th place.
Finally, there are many companies that have AI applications, but not necessarily as their core product. This includes names like Databricks (a data analytics platform), Grammarly (uses generative AI to power its writing assistant), and Colossal (a de-extinction biotech company).
If you enjoyed today’s post, check out History’s Most Valuable Companies vs the Magnificent 7 on Voronoi, the new app from Visual Capitalist.
2025-07-31 21:11:00
Pharma giants don’t just make medicine—they shape the future of healthcare. From determining which treatments reach patients to setting costs and driving innovation, their influence extends across both health outcomes and financial markets.
This visualization, created in partnership with Inigo Insurance, ranks the largest pharmaceutical companies in the world by market capitalization, using data from companiesmarketcap.com.
Eli Lilly dominates the industry with a staggering market cap of $686 billion, nearly double that of Johnson & Johnson, the second largest company, at $359 billion. Eli Lilly’s value has skyrocketed since 2020, climbing from roughly $130 billion, largely fueled by the runaway success of its weight-loss drugs, Mounjaro and Zepbound.
| Rank | Company Name | Market Cap ($ billions) |
|---|---|---|
| 1 | Eli Lilly | 686 |
| 2 | Johnson & Johnson | 359 |
| 3 | Novo Nordisk | 334 |
| 4 | AbbVie | 327 |
| 5 | Roche | 255 |
| 6 | Novartis | 229 |
| 7 | AstraZeneca | 217 |
| 8 | Merck | 200 |
| 9 | Amgen | 156 |
| 10 | Pfizer | 136 |
| 11 | Gilead Sciences | 135 |
| 12 | Sanofi | 116 |
| 13 | Vertex Pharmaceuticals | 113 |
| 14 | Bristol-Myers Squibb | 96 |
| 15 | CVS Health | 85 |
| 16 | Chugai Pharmaceutical | 81 |
| 17 | GlaxoSmithKline | 78 |
| 18 | CSL | 75 |
| 19 | Zoetis | 70 |
| 20 | Merck KGaA | 55 |
Indeed, in the first quarter of 2025, worldwide revenue increased 45% to $12.73 billion, driven by volume growth from Mounjaro and Zepbound.
There are three other companies with market caps above $300 billion: Johnson & Johnson with $359 billion, Novo Nordisk with $334 billion, and AbbVie with $327 billion.
Novo Nordisk also benefited from the weight-loss drug boom, with products like Ozempic and Wegovy driving growth. However, after peaking near $640 billion in mid-2024, its valuation has since cooled.
Roche, valued at $255 billion, joins other major players alongside Novartis at $229 billion, AstraZeneca at $217 billion—one of the first companies to release a COVID-19 vaccine—and Merck at $200 billion.
Pfizer ranks 10th with a market cap of $136 billion and is best known for blockbuster drugs like Viagra. Merck KGaA holds the 20th spot with a valuation of $55 billion, carrying the distinction of being the world’s oldest pharmaceutical company, founded in Germany in 1668.
Doctors prescribe and patients decide, but pharma giants ultimately control which drugs they develop, who gets access, and what price they charge. Understanding who dominates this $5.6 trillion industry provides critical insight into the future of healthcare.
Explore Inigo’s Hub.
The pharmaceutical industry has made enormous strides in treating—and even curing—a wide range of diseases and conditions. Which areas are seeing the most R&D in 2025?
The fraud and financial crime landscapes are evolving rapidly. What are the key threats shaping risk in 2025?
Some of the largest digital heists didn’t rely on brute-force hacking, they exploited the weakest link in security: human trust.
As cybersecurity threats escalate, which financial crimes are causing the most harm? The FBI has the data.
Suspicious activity has been rising in the U.S., but is it spread evenly throughout all 50 states? Certainly not.
As technology and AI become more widespread, fraud and other suspicious activity are rising across America. Which types are the most common?
From money laundering to fraud, financial crime acts as a drain on the economy, totaling an incredible $3.1 trillion.
Over half the global population is ruled by non-centrist types of government, including autocracies and left or right wing parties.
Ukraine will require an estimated $524B over the next decade to recover from the Russia-Ukraine war. Which sectors have been most impacted?
Amid tariff increases, consumers’ expectations for U.S. inflation in the next five years have reached their highest level since March 1991.
In his first 100 days, President Trump has issued far more executive orders than any other president in history.
2025-07-31 20:08:03
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.
The rise of today’s tech giants has redefined market dominance. Companies like Nvidia, Microsoft, and Apple, which form the Magnificent Seven, boast multi-trillion-dollar valuations, but how do they compare to the titans of history?
In this visualization, we compare the market capitalization of Magnificent Seven stocks to three of history’s biggest companies.
The data for this visualization originates from a 2012 post by The Motley Fool, which compared peak inflation-adjusted valuations of historical monopolies.
We adjusted these values to current dollars, then compared them to the Magnificent Seven as of July 18, 2025.
| Company | Year | Value (USD trillions) |
|---|---|---|
 Dutch East IndiaCompany (VOC) |
1637 (peak valuation) |
$10.15 |
 Mississippi Company |
1720 (peak valuation) |
$8.35 |
 South Sea Company |
1720 (peak valuation) |
$5.52 |
 NVIDIA |
2025 | $4.20 |
|
Microsoft |
2025 | $3.79 |
|
Apple |
2025 | $3.15 |
|
Amazon |
2025 | $2.40 |
|
Alphabet |
2025 | $2.25 |
|
Meta |
2025 | $1.77 |
|
Tesla |
2025 | $1.06 |
Founded in 1602, the Dutch East India Company (VOC) peaked at a valuation of over $10 trillion in today’s dollars.
Backed by government charters and global monopolies, the VOC controlled huge parts of the spice trade, giving it unmatched economic power in its time. VOC could acquire exotic goods, establish colonies, create military forces, and even initiate wars around the world.
Despite its 200-year run as Europe’s foremost trading juggernaut – the speculative peak of the company’s prospects coincided with Tulip Mania in Holland in 1637.
Widely considered the world’s first financial bubble, the history of Tulip Mania is a fantastic story in itself. During this frothy time, the Dutch East India Company was worth 78 million Dutch guilders, which translates to a whopping $10.2 trillion in today’s dollars.
The other historical companies in this graphic, Mississippi Company and South Sea Company, both peaked in 1720 amid massive speculative bubbles.
At their heights, their valuations hit $8.35 trillion and $5.52 trillion respectively. However, both collapsed shortly after, serving as early examples of market euphoria and financial instability.
For example, the Mississippi Company was a French trading venture with exclusive rights to develop France’s Mississippi/Louisiana territories. Investors were lured by speculation of the vast wealth from Louisiana’s natural resources (e.g. gold), but no profits ever came.
If you enjoyed today’s post, check out The Complete History of Microsoft’s Acquisitions on Voronoi, the new app from Visual Capitalist.
2025-07-31 18:40:54
See this visualization first on the Voronoi app.
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data‑driven charts from a variety of trusted sources.
From indoor plumbing to pocket‑sized computers, the arc of U.S. prosperity can be traced through the everyday items that migrated from luxury to necessity. Examining when households first gained access to these utilities and gadgets reveals how economic growth translates into tangible improvements in daily life—and offers a roadmap for tracking progress in today’s emerging markets.
The visualization above, created by Our World in Data (Max Roser), pairs 160 years of U.S. GDP‑per‑capita data with the share of households that own—or simply have access to—everyday necessities.
Economic historian Jeremy Greenwood calls household technologies the “engines of liberation” because they turn income into comfort and time‑saving capacity.
Refrigerators and vacuum cleaners, for example, swept into more than 70% of homes within two decades of commercial viability, mirroring the earlier diffusion of running water and electric light. By 1970, the typical American household owned goods that were science fiction just 50 years earlier. Next, computers and mobile phones leapt from niche to mainstream in a single generation, echoing earlier booms in radio and television.
Together, these trends show how higher output translated into tangible improvements inside the home—arguably the place people feel growth most directly.
Traditional growth metrics like GDP or real wages conceal what economist Angus Deaton terms the “lived experience” of prosperity.
Tracking adoption rates offers a complementary lens: it tells us not just how big the economy is, but how its gains permeate daily life. A flat income series may hide the fact that color TVs or air‑conditioning are suddenly affordable to all. Work by the National Bureau of Economic Research shows that such quality‑adjusted gains mean living standards rise faster than official estimates suggest.
The U.S. timeline is now a benchmark for catch‑up development. When researchers compare electrification in India or smartphone uptake in Nigeria, they use similar s‑curves to map progress. Because technology costs fall globally, many emerging economies leapfrog stages—adopting mobile phones, for instance, long before landlines ever became universal. Using access indicators therefore paints a richer picture of growth than per‑capita income alone, and it helps policymakers target bottlenecks in infrastructure and affordability.
Explore more insights into income inequality and economic growth on the Voronoi app, including how daily incomes have changed across the top 20 economies since 1994.
